Does the Use of the “Proseek® Multiplex Inflammation I Panel” Demonstrate a Difference in Local and Systemic Immune Responses in Endometriosis Patients with or without Deep-Infiltrating Lesions?
by
, , , , ,
Alexandra Perricos
1,
Heinrich Husslein
1,
Lorenz Kuessel
1,
Manuela Gstoettner
1,
Andreas Weinhaeusel
2,
Thomas Eiwegger
3,4,5,6,7,
Gabriel Beikircher
2 and
René Wenzl
1,* 1
Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria
2
Molecular Diagnostics, Center for Health & Bioresources, AIT Austrian Institute of Technology Vienna, 1210 Vienna, Austria
3
Translational Medicine Program, Research Institute, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
4
Departments of Pediatric, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
5
Departments of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
6
Medical Faculty, Karl Landsteiner University of Health Sciences, 3500 Krems an der Donau, Austria
7
Department of Pediatric and Adolescent Medicine, University Hospital St. Pölten, 3100 St. Pölten, Austria
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(5), 5022; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24055022
Submission received: 24 December 2022
/
Revised: 16 February 2023
/
Accepted: 27 February 2023
/
Published: 6 March 2023
(This article belongs to the Special Issue Recent Advances in Endometriosis Pathophysiology and Pharmacological Treatment)
Abstract
:Endometriotic lesions are able to infiltrate surrounding tissue. This is made possible partly by an altered local and systemic immune response that helps achieve neoangiogenesis, cell proliferation and immune escape. Deep-infiltrating endometriosis (DIE) differs from other subtypes through the invasion of its lesions over 5 mm into affected tissue. Despite the invasive nature of these lesions and the wider range of symptoms they can trigger, DIE is described as a stable disease. This elicits the need for a better understanding of the underlying pathogenesis. We used the “Proseek® Multiplex Inflammation I Panel” in order to simultaneously detect 92 inflammatory proteins in plasma and peritoneal fluid (PF) of controls and patients with endometriosis, as well as in particular patients with DIE, in order to gain a better insight into the systemically and locally involved immune response. Extracellular newly identified receptor for advanced gycation end-products binding protein (EN-RAGE), C-C motif Chemokine ligand 23 (CCL23), Eukaryotic translation initiation factor 4—binding protein 1 (4E-BP1) and human glial cell-line derived neurotrophic factor (hGDNF) were significantly increased in plasma of endometriosis patients compared to controls, whereas Hepatocyte Growth factor (HGF) and TNF-related apoptosis inducing ligand (TRAIL) were decreased. In PF of endometriosis patients, we found Interleukin 18 (IL-18) to be decreased, yet Interleukin 8 (IL-8) and Interleukin 6 (IL-6) to be increased. TNF-related activation-induced cytokine (TRANCE) and C-C motif Chemokine ligand 11 (CCL11) were significantly decreased in plasma, whereas C-C motif Chemokine ligand 23 (CCL23), Stem Cell Factor (SCF) and C-X-C motif chemokine 5 (CXCL5) were significantly increased in PF of patients with DIE compared to endometriosis patients without DIE. Although DIE lesions are characterized by increased angiogenetic and pro-inflammatory properties, our current study seems to support the theory that the systemic immune system does not play a major role in the pathogenesis of these lesions.
1. Introduction
Endometriosis is a benign gynecological disease, defined as the implantation of endometrial-like tissue outside of the uterine cavity [1], occurring with a prevalence of 6–10% in women of reproductive age [2]. Its clinical presentation varies from asymptomatic women to patients suffering from dysmenorrhea, dyspareunia, dyschezia, dysuria and/or infertility [1]. Due to this range of possible symptoms, diagnosis is often delayed, in many cases taking a great toll on the quality of life of affected women [3]. The unacceptably long time to diagnosis, which has reported to be over eight years, on average, for women suffering from pelvic pain [4], calls for a better understanding of the disease itself and new, non-invasive biomarkers.
Depending on the locations and characteristics of the lesions, three endometriosis subtypes have been defined: (superficial) peritoneal lesions, ovarian endometriosis cysts (known as endometriomas) and deep-infiltrating endometriosis (DIE), defined as an infiltration of ≥5 mm into the surrounding tissue, such as, more commonly, the uterosacral ligaments, the bladder or the rectum [5]. Due to its wide range of symptoms, this endometriosis subtype is known to potentially have a severe impact on patient’s quality of life [6]. This underlines the importance of an adequate choice of treatment. Treatment options include a conservative as well as a surgical approach. The choice should be based on the patient’s medical history, symptoms, extent of the disease and personal preference [7]. Despite the invasive nature of these lesions and the wider range of symptoms they can trigger, DIE is described as a stable disease [8].
The exact pathophysiology of this disease still remains unknown. Numerous studies over the years have described inflammation as a key feature in the pathogenesis of endometriosis. Endometriotic lesions are characterized by their ability to implant and proliferate [9,10], thus infiltrating the surrounding tissue [11], triggering neoangiogenesis and an invasion of nerve fibers [12]. Important for their survival is not only their resistance to apoptosis, but also their escape from immune surveillance [13,14]. The first line of defense against any aberrant cells, be it tumor cells or virus-infected cells, are, amongst others, natural killer cells (NK-cells), macrophages, granulocytes and mast cells. These innate cells secrete chemokines (notably from the CC- and CXCL family) and cytokines which recruit additional leukocytes and form the basis for chronic inflammation [15]. In addition, also non hematopoietic cells can contribute to inflammation. This partially explains why high concentrations of these inflammatory proteins have been observed in context with low concentration of NK-cells in the peritoneal milieu of women with endometriosis [14]. Chronicity and lack of clearance of inflammation may be maintained by an impairment of the phagocyting capacities of attracted macrophages [15].
A simultaneous detection of different proteins involved in inflammatory processes has been made possible by multiplex technologies. Several studies have evaluated the usefulness of multiplex technologies for the detection of proteins associated with endometriosis [16,17]. While the analysis of inflammatory proteins in plasma may offer information about the systemic conditions brought on by the disease, the analysis of peritoneal fluid (PF) has established itself as a useful tool to learn more about the local environment of pelvic endometriotic lesions.
In this study, we used the “Proseek® Multiplex Inflammation I Panel” in order to expand our understanding of the local intraperitoneal as well as systemic inflammatory mechanisms that underlie the pathogenesis of endometriosis. First, we sought to compare patients suffering from endometriosis to controls to define differences in the immune response brought on by the disease itself. Since characteristics of the endometriosis subtypes differ from each other, we then attempted to define distinct local and systemic inflammatory properties of patients with deep-infiltrating endometriotic lesions.
2. Results
Eighty-four patients were included in our study. In three of these study participants, however (one patient with endometriosis without DIE, one patient with DIE and one control), ≥50% of markers were found to be under the limit of detection (LOD), either in plasma or in PF. These three patients were therefore excluded from further analysis. Thus, 81 patients were included in the final calculations, 51 patients with endometriosis (18 of which suffered from DIE) and 30 controls. Patient characteristics are summarized in Table 1.
For further data evaluation, we disregarded 23 (underlined in the Supplemental Table S1) out of the 92 analyzed proteins in PF, because they were expressed in less than 50% of patients. The same was carried out for 16 proteins (set in bold in the Supplemental Table S1) measured in plasma.
2.1. Patients with Endometriosis vs. Controls
The first step of this study focused on comparing all patients with endometriosis to controls, regarding local and systemic inflammatory response. Table 2 presents the markers that differed significantly between the two groups, in both plasma and PF. Heat maps of these proteins are shown in Figure 1 (plasma) and Figure 2 (PF).
In plasma, four proteins were significantly increased in endometriosis patients, notably the Extracellular Newly identified Receptor for Advanced Glycation End-products binding protein (EN-RAGE—1.63-fold), Chemokine ligand 23 (CCL23—1.22-fold), Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1—1.43-fold) and human Glial-derived Neurotrophic factor (hGDNF—1.12-fold), whereas Hepatocyte Growth Factor (HGF) and TNF-Related Apoptosis Inducing Ligand (TRAIL) were significantly decreased in this patient group.
When analyzing PF, we merely found three protein concentrations that significantly differed between the groups: Interleukin-6 (IL-6) and Interleukin-8 (IL-8) were increased (2.13- and 2.68-fold respectively), while Interleukin-18 (IL-18) was decreased 0.67-fold in PF of women suffering from endometriosis, compared to controls.
2.2. Patients with DIE vs. Patients with Endometriosis without DIE
In order to determine the influence of a deep-infiltrating lesion on the local and systemic inflammatory milieu, we compared the inflammation markers in plasma and PF of patients with DIE to women with endometriosis but without DIE. The proteins that differed significantly between these groups are summarized in Table 3. Heat maps of these proteins are shown in Figure 3 (plasma) and Figure 4 (PF).
In plasma, two proteins were significantly decreased in patients with DIE. Tumor necrosis factor-related activation-induced cytokine (TRANCE) and chemokine (C-C Motif) ligand 11 (CCL11) were decreased 0.70- and 0.84-fold, respectively, in patients with DIE. In PF four proteins were increased in patients with deep-infiltrating lesions: CCL23 (1.7-fold), CCL11 (1.46-fold), Stem Cell Factor (SCF—1.23-fold) and C-X-C motif chemokine 5 (CXCL5—2.54-fold).
3. Discussion
The key role of inflammatory processes in the development of endometriosis and its lesions has been evaluated in multiple studies. While many theories have been discussed regarding the pathogenesis of endometriosis, many questions still remain to be answered. In our study, we used a multiplex technology which enabled a simultaneous detection of inflammatory proteins in PF and plasma of patients suffering from endometriosis and controls, in hopes of gaining new insights into underlying pathophysiological mechanisms of endometriosis, and especially of DIE.
We therefore performed two sub-analyses in our study, comparing plasma and PF of patients with endometriosis to samples of controls, and in a second step, comparing patients suffering from DIE to endometriosis patients without deep-infiltrating lesions.
3.1. Patients with Endometriosis vs. Controls
In Table 4 we summarize the main characteristics of proteins that were significantly increased or decreased in patients suffering from endometriosis compared to controls.
Two markers (EN-RAGE and CCL23) known for their chemoattractant characteristics were found to be increased in plasma of endometriosis patients compared to controls.
EN-RAGE genes were found to be significantly higher expressed in endometrial stromal cells (ESC) in endometriosis patients compared to controls by Sharma et al. [32]. EN-RAGE expression seems to be upregulated by its own receptor, RAGE, the expression of which might in turn be activated by estradiol. This led to the conclusion that EN-RAGE might play an important role in the altered inflammatory response in endometriosis patients. Interestingly, an increased expression of EN-RAGE in ESC as described by Sharma would consequently result in an increased expression in PF. Our data, however, merely showed a significant systemic and not local increase in EN-RAGE, as it was increased in plasma and not in PF. CCL23 has never, to our knowledge, been associated with endometriosis in previous studies. Our analysis, however, showed a significant systemic increase in endometriosis patients.
The association between HGF and endometriosis has been described in numerous studies [7], promoting cell proliferation and angiogenesis [22], two central characteristics of endometriotic lesions. Most studies, however, focused on the local HGF production, measured in PF, rather than on its systemic expression. Recently, Zhang et al. showed a significantly increased expression of HGF in serum of patients suffering from endometriosis compared to controls, and in particular an increased expression in endometriosis stages III and IV, suggesting that this protein might be used as a future biomarker for diagnosing more advanced stages of this disease [33]. In contrast, we found this protein to be significantly decreased in plasma of patients suffering from various stages of endometriosis. This puts into question the validity of HGF as a future biomarker for this disease.
Gene expression of 4EBP1was found to be increased in eutopic endometrium of endometriosis patients yet decreased in ovarian endometriotic lesions in these patients [34]. These changes could not, however, be sufficiently explained.
The main function of TRAIL lies in its ability to induce apoptosis. Kim et al. showed results similar to those found in our analyses, with a reduced TRAIL expression in serum of women suffering from endometriosis [35], a trait also seen in some types of cancer cells [26]. This downregulated TRAIL expression might play a significant role in the resistance of endometriotic lesions to apoptosis.
Very little data have been published to date regarding the involvement of hGDNF in endometriotic lesions. Chang et al. and Streiter et al. demonstrated the importance of this neurotrophic factor in normal ovarian function and follicular development and suggested that an altered expression might lead to the development of ovarian diseases such as polycystic ovary syndrome (PCOS) or endometriosis [36,37]. To our knowledge, the only study that evaluated a direct link of this protein to endometriosis showed an increased expression in the glandular epithelium of peritoneal ectopic lesions compared to stroma and surrounding peritoneum [38].
In PF of endometriosis patients compared to controls, three pro-inflammatory cytokines (IL-6, IL-8 and IL-18) were significantly differently expressed. The data published regarding IL-18 expression in endometriosis patients show discrepant results. Our results are in line with those described by Zhang et al.: Here too, IL-18 expression was significantly reduced in PF of patients with endometriosis, while this did not correlate with expression in plasma. This finding was used to explain the known reduced NK-cell activity and impaired T-helper-cell immune response seen in patients with endometriosis [39]. In contrast, Oku et al. reported no differences in circulating IL-18 concentrations between these two groups, however, a significantly increased expression in PF of affected patients [40], while Glitz et al. described no differences in serum or PF regarding IL-18 expression but showed a strong positive correlation between serum and PF IL-18 levels [41].
On the other hand, IL-6 and IL-8 were overexpressed in PF of women suffering from endometriosis, which underlines the local pro-inflammatory environment seen in our patient collective. Our data confirm the results found by Wang et al., who described a proliferation-stimulating effect on peritoneal endometriotic lesions [42]. Li et al. further postulated that the increased IL-6 expression induced by macrophages increases secretion of haptoglobin, which in turn helps endometriotic cells escape immune surveillance by binding to macrophages and thus decreasing phagocytosis [43]. As shown in the review by Sikora et al., the increased expression of Il-8 is thought to be linked to an increased expression of other pro-inflammatory factors such as IL-1 and TNF-alpha in patients with endometriosis [31]. Furthermore, it was shown that IL-8 production in human endometrial endothelial cells (HEEC) is stimulated by estrogen and progesterone in women with endometriosis, while these steroid hormones do not have the same effect on HEEC in women without endometriosis [44].
3.2. Patients with DIE vs. Endometriosis Patients without DIE
Table 5 summarizes the main characteristics of proteins that were significantly increased or decreased in patients with DIE compared to endometriosis patients without DIE.
DIE differs from other endometriosis subtypes in that these lesions penetrate exceeding 5 mm into surrounding tissue. Because of its particular characteristics, the understanding of the pathophysiology of this subtype has become the center of recent studies. Although DIE should not be considered a progressive disease, the impact on patient’s symptoms and the challenges for surgeons dealing with these lesions are high [8].
Zhou et al. recently described different cytokine signatures differentiating between the three previously mentioned subtypes of the disease (peritoneal, ovarian and deep-infiltrating endometriosis). The authors used a multiplex assay of 48 cytokines on PF of endometriosis patients and found a six-cytokine signature of IL-8, IL-12p70, IL-16, IL-18, MCP-1 and MIP-1α, all upregulated in patients with DIE compared to peritoneal endometriosis, as well as a seven-cytokine signature comprising IL-1α, IL-1RA, IL-8, IL-12p40, IL-12p70, IL-16 and TNF-α when comparing patients with ovarian endometriomas and patients with DIE [51]. Although several of these cytokines (IL-8, IL-18, MCP-1 and IL-1α) were included in our analysis, we could not find any corresponding results in our samples.
Compared to endometriosis patients without DIE, two proteins were found to be significantly decreased in plasma of patients with DIE.
To our knowledge, TRANCE has never been connected to the pathophysiology of endometriosis. Our data show lower values in plasma of patients suffering from DIE, which might contribute to immune escape seen in endometriotic lesions.
The important role of CCL11 in endometriotic lesions has been attributed to its recently described angiogenetic potency [52]. In our collective, we found the chemoattractant CCL11 to be diminished in plasma of patients suffering from DIE yet increased in PF of these patients. While in our samples CCL11 concentrations merely differed in patients with DIE compared to endometriosis patients without DIE, previously published data showed lower values in serum [53] and increased values in PF of endometriosis patients compared to controls [26], which correlated with the endometriosis rASRM stage.
Suzumori et al. have described significantly elevated levels of CXCL5 in PF of endometriosis patients compared to controls, in particular, however, in patients suffering from more severe stages (stage III and IV) [54]. While our data merely showed differences between DIE and patients without DIE, this may be attributed to the fact that we had significantly more patients with moderate to severe endometriosis in the DIE group. Furthermore, Wunder et al. reported an increased concentration of the chemokine in follicular fluid (FF) of patients with endometriosis. As FF contributes to PF during ovulation, this might add to the inflammatory milieu as well as implantation and neovascularization of endometriotic lesions [55]. An overexpression of CXCL5 has also been previously described in deep-infiltrating lesions themselves, notably in rectovaginal lesions [56].
Another cytokine involved in neoangiogenesis is the previously mentioned CCL23. This cytokine was found to be significantly overexpressed in our patient collective suffering from DIE compared to endometriosis patients without DIE, which might suggest an increased vascularization of these lesions.
Osuga et al. analyzed the concentration of SCF in plasma and PF of patients with endometriosis and controls. The authors described an increased expression of SCF only in PF of affected patients. When comparing patients according to their endometriosis rASRM stage, this significant difference was only maintained in patients with stages I and II, compared to controls [49]. Here, it is important to consider, however, that the rASRM score solely takes into account intraperitoneal lesions and does not offer any insight into the extent of possible deep-infiltrating lesions. In our analysis, we found significantly higher SCF concentrations in PF samples of patients with DIE compared to endometriosis patients without DIE. This reconfirms the role of SCF in local inflammation.
In vivo data have shown that there seems to be a causal effect of a systemic immune response on the development of endometriotic lesions [57]. However, further studies are needed to clarify whether the role of the immune systems is truly causal or merely a consequence of this disease.
In conclusion, while the important role of inflammatory processes in the development and persistence of endometriotic lesions has been repeatedly demonstrated, our multiplex analysis of 92 inflammatory proteins failed to show drastic differences regarding local and systemic inflammatory response in patients suffering from endometriosis compared to controls. Surprising to us were especially the very few differences found in patients with deep-infiltrating lesions. As such, we believe it may be difficult to identify biomarkers that allow the non-invasive diagnosis of DIE. Although these lesions invade deeper into surrounding tissue and create more anatomic distortions, adhesions and tissue fibrosis, our data showed only few differences regarding inflammatory marker levels measured in the “Proseek® Multiplex Inflammation I Panel” in patients suffering from DIE. Although DIE is a subtype characterized by increased angiogenetic and pro-inflammatory properties [58], our current study seems to support the theory that the systemic immune system does not play a major role in the pathogenesis of DIE lesions. The differences seen in published data on inflammatory processes in endometriosis, and in particular DIE, suggest that further studies might be necessary in order to fully understand the role of these cytokines in this enigmatic disease.
4. Materials and Methods
4.1. Patients
The plasma and peritoneal fluid (PF) samples were collected as part of the Endometriosis Marker Austria (EMMA) study, a prospective cohort study conducted at the tertiary, certified referral Endometriosis Center. This study was approved by the Ethics Committee of the Medical University of Vienna (EK 545/2010). The premenopausal patients selected for this particular study were between 18 and 50 years of age and all underwent laparoscopic surgery during the period of 2010 to 2015 at the Department of Obstetrics and Gynecology at the Medical University of Vienna, for suspected endometriosis, benign ovarian cysts, uterine fibroids, chronic pelvic pain or infertility. All patients included in the “endometriosis group” all had histologically confirmed endometriotic lesions, whereas patients without endometriosis were defined as the “control group”. During the surgery, the endometriosis cases were scored according the rASRM score as minimal (I), mild (II), moderate (III) or severe (IV). In cases of DIE, the disease was furthermore classified according to the ENZIAN scoring system.
Information on baseline patient characteristics such as age, BMI, gravidity, parity, as well as the intensity of endometriosis-associated symptoms, notably dysmenorrhea and dyspareunia evaluated using the visual analog scale (VAS), was obtained preoperatively. Statistical testing on patient characteristics included Chi-squared tests, parametric t-tests and Mann–Whitney-U test, and was performed using IBM SPSS statistics version 27.
4.2. Sample Analysis
Citrate plasma and PF were collected prospectively in accordance with the harmonization guidelines, plasma in a fasting state in the morning on the day of surgery, and peritoneal fluid after a lavage of the peritoneal cavity with 10 mL of sterile 0.9% NaCl. The samples were immediately centrifuged (plasma at 1000 rounds per minute (rpm) and PF at 3000 rpm at 4 °C for ten minutes) and stored in aliquots at −80 °C until analysis.
Ninety-two proteins were measured simultaneously using the “Proseek® Multiplex Inflammation I Panel” (OLINK Proteomics, Uppsala, Sweden). A list of all analyzed proteins is shown in Supplemental Table S1.
The measurement was carried out according to the Proseek Multiplex 96 × 96 User Manual. Specifically, the Proseek reagents are based on Proximity Extension Assay technology, in which 96 oligonucleotide-labeled antibody probe pairs bind to their respective protein targets in the sample. A polymerase chain reaction (PCR) reporter is formed by a proximity-dependent DNA polymerization event which is detected and quantified by real-time PCR, generating quantitative values in arbitrary units.
The Fluidigm raw data’s quality was assessed according to OLINK guidelines (Data Preprocessing v1.0). Values in PF were normalized to the total protein amount (measured with the Bradford Assay) in order to compensate for technical differences due to potentially slightly different lavage volumes during PF sample collection.
Biostatistical analysis was performed using BRB Array Tools Version 4.4.1 (developed by the National Cancer Institute, National Institute of Health, Bethesda, United States) and included class comparison (conducted at a significance level of 0.05), whereby different feature selection criteria were applied. The Normalized Protein eXpression (NPX) values were imported into BRB Tools, whereby all normalization methods were disabled, since the data gained in PF were already normalized in the data preprocessing procedure. According to BRB Array Tools software, the log2 transformed data were used for multiplex data analysis, and geometric mean as well as linear fold change between the groups (patients with endometriosis vs. controls and endometriosis with DIE vs. endometriosis patients without DIE) were calculated [58].
Supplementary Materials
The supporting information can be downloaded at: https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/ijms24055022/s1.
Author Contributions
Conceptualization: R.W., T.E. and M.G.; methodology: G.B. and A.W.; software: G.B. and A.W.; validation: R.W., L.K., H.H., G.B. and A.W.; formal analysis: G.B. and A.W.; investigation: R.W., L.K., H.H., G.B., A.W. and M.G.; resources: R.W., L.K., H.H., G.B. and A.W.; data curation: G.B. and A.W.; writing—original draft preparation: A.P. and R.W.; writing—review and editing: A.P., R.W., L.K., T.E., H.H., A.W. and M.G.; visualization: A.P., R.W., G.B. and A.W.; supervision: R.W.; project administration: R.W. and M.G. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Vienna (EK 545/2010).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The authors confirm that the data supporting the findings of this study are available within the article.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Zondervan, K.T.; Becker, C.M.; Missmer, S.A. Endometriosis. N. Engl. J. Med. 2020, 382, 1244–1256. [Google Scholar] [CrossRef]
- Burney, R.O.; Giudice, L.C. Pathogenesis and pathophysiology of endometriosis. Fertil. Steril. 2012, 98, 511–519. [Google Scholar] [CrossRef] [Green Version]
- Buggio, L.; Barbara, G.; Facchin, F.; Frattaruolo, M.P.; Aimi, G.; Berlanda, N. Self-management and psychological-sexological interventions in patients with endometriosis: Strategies, outcomes, and integration into clinical care. Int. J. Women’s Health 2017, 9, 281–293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Staal, A.; van der Zanden, M.; Nap, A. Diagnostic Delay of Endometriosis in the Netherlands. Gynecol. Obstet. Investig. 2016, 81, 321–324. [Google Scholar] [CrossRef] [PubMed]
- Nisolle, M.; Donnez, J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil. Steril. 1997, 68, 585–596. [Google Scholar] [CrossRef]
- D’Alterio, M.N.; Saponara, S.; Agus, M.; Laganà, A.S.; Noventa, M.; Loi, E.S.; Feki, A.; Angioni, S. Medical and surgical interventions to improve the quality of life for endometriosis patients: A systematic review. Gynecol. Surg. 2021, 18, 13. [Google Scholar] [CrossRef]
- D’Alterio, M.N.; D’Ancona, G.; Raslan, M.; Tinelli, R.; Daniilidis, A.; Angioni, S. Management Challenges of Deep Infiltrating Endometriosis. Int. J. Fertil. Steril. 2021, 15, 88–94. [Google Scholar] [CrossRef]
- Koninckx, P.R.; Ussia, A.; Adamyan, L.; Wattiez, A.; Donnez, J. Deep endometriosis: Definition, diagnosis, and treatment. Fertil. Steril. 2012, 98, 564–571. [Google Scholar] [CrossRef]
- Kyama, C.M.; Overbergh, L.; Debrock, S.; Valckx, D.; Vander Perre, S.; Meuleman, C.; Mihalyi, A.; Mwenda, J.M.; Mathieu, C.; D’Hooghe, T.M. Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis. Fertil. Steril. 2006, 85, 1667–1675. [Google Scholar] [CrossRef] [Green Version]
- Vercellini, P.; Viganò, P.; Somigliana, E.; Fedele, L. Endometriosis: Pathogenesis and treatment. Nat. Rev. Endocrinol. 2014, 10, 261–275. [Google Scholar] [CrossRef] [PubMed]
- MWu, M.-H.; Yang, B.-C.; Hsu, C.-C.; Lee, Y.-C.; Huang, K.-E. The expression of soluble intercellular adhesion molecule-1 in endometriosis. Fertil. Steril. 1998, 70, 1139–1142. [Google Scholar] [CrossRef]
- Giudice, L.C. Clinical practice. Endometriosis. N. Engl. J. Med. 2010, 362, 2389–2398. [Google Scholar] [CrossRef]
- Reis, F.M.; Petraglia, F.; Taylor, R.N. Endometriosis: Hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum. Reprod. Updat. 2013, 19, 406–418. [Google Scholar] [CrossRef] [Green Version]
- Oosterlynck, D.J.; Meuleman, C.; Waer, M.; Vandeputte, M.; Koninckx, P.R. The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis. Fertil. Steril. 1992, 58, 290–295. [Google Scholar] [CrossRef]
- Lebovic, I.D.; Mueller, M.D.; Taylor, R.N. Immunobiology of endometriosis. Fertil. Steril. 2001, 75, 1–10. [Google Scholar] [CrossRef]
- Jørgensen, H.; Hill, A.S.; Beste, M.T.; Kumar, M.P.; Chiswick, E.; Fedorcsak, P.; Isaacson, K.B.; Lauffenburger, D.A.; Griffith, L.G.; Qvigstad, E. Peritoneal fluid cytokines related to endometriosis in patients evaluated for infertility. Fertil. Steril. 2017, 107, 1191–1199.e2. [Google Scholar] [CrossRef] [Green Version]
- Knific, T.; Fishman, D.; Vogler, A.; Gstöttner, M.; Wenzl, R.; Peterson, H.; Rižner, T.L. Multiplex analysis of 40 cytokines do not allow separation between endometriosis patients and controls. Sci. Rep. 2019, 9, 16738. [Google Scholar] [CrossRef]
- Mahajan, N.; Malik, N.; Bahl, A.; Dhawan, V. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009, 207, 597–602. [Google Scholar] [CrossRef]
- Wu, R.; Liu, Y.; Yan, R.; Liu, X.; Duan, L. Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis. J. Transl. Med. 2020, 18, 384. [Google Scholar] [CrossRef]
- Korbecki, J.; Kojder, K.; Simińska, D.; Bohatyrewicz, R.; Gutowska, I.; Chlubek, D.; Baranowska-Bosiacka, I. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int. J. Mol. Sci. 2020, 21, 8412. [Google Scholar] [CrossRef]
- Faura, J.; Bustamante, A.; Penalba, A.; Giralt, D.; Simats, A.; Martínez-Sáez, E.; Alcolea, D.; Fortea, J.; Lleó, A.; Teunissen, C.E.; et al. CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer’s Disease. J. Alzheimer’s Dis. 2020, 73, 1585–1595. [Google Scholar] [CrossRef]
- Khan, K.N.; Kitajima, M.; Hiraki, K.; Fujishita, A.; Sekine, I.; Ishimaru, T.; Masuzaki, H. REVIEW ARTICLE: Immunopathogenesis of Pelvic Endometriosis: Role of Hepatocyte Growth Factor, Macrophages and Ovarian Steroids. Am. J. Reprod. Immunol. 2008, 60, 383–404. [Google Scholar] [CrossRef] [Green Version]
- Kwon, Y.; Godwin, A.K. Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction. Reprod. Sci. 2016, 24, 494–501. [Google Scholar] [CrossRef] [Green Version]
- William, M.; Leroux, L.-P.; Chaparro, V.; Lorent, J.; Graber, T.E.; M’Boutchou, M.-N.; Charpentier, T.; Fabié, A.; Dozois, C.M.; Stäger, S.; et al. eIF4E-Binding Proteins 1 and 2 Limit Macrophage Anti-Inflammatory Responses through Translational Repression of IL-10 and Cyclooxygenase-2. J. Immunol. 2018, 200, 4102–4116. [Google Scholar] [CrossRef] [Green Version]
- Musa, J.; Orth, M.F.; Dallmayer, M.; Baldauf, M.; Pardo, C.; Rotblat, B.; Kirchner, T.; Leprivier, G.; Grünewald, T.G.P. Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): A master regulator of mRNA translation involved in tumorigenesis. Oncogene 2016, 35, 4675–4688. [Google Scholar] [CrossRef]
- Oikonomou, E.; Pintzas, A. The TRAIL of oncogenes to apoptosis. Biofactors 2013, 39, 343–354. [Google Scholar] [CrossRef]
- Woodbury, D.; Schaar, D.G.; Ramakrishnan, L.; Black, I.B. Novel structure of the human GDNF gene. Brain Res. 1998, 803, 95–104. [Google Scholar] [CrossRef]
- Yasuda, K.; Nakanishi, K.; Tsutsui, H. Interleukin-18 in Health and Disease. Int. J. Mol. Sci. 2019, 20, 649. [Google Scholar] [CrossRef] [Green Version]
- Tanaka, T.; Narazaki, M.; Kishimoto, T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb. Perspect. Biol. 2014, 6, a016295. [Google Scholar] [CrossRef]
- Kumari, N.; Dwarakanath, B.S.; Das, A.; Bhatt, A.N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol. 2016, 37, 11553–11572. [Google Scholar] [CrossRef]
- Sikora, J.; Smycz-Kubańska, M.; Mielczarek-Palacz, A.; Kondera-Anasz, Z. Abnormal peritoneal regulation of chemokine activation-The role of IL-8 in pathogenesis of endometriosis. Am. J. Reprod. Immunol. 2017, 77, e12622. [Google Scholar] [CrossRef]
- Sharma, I.; Dhawan, V.; Saha, S.C.; Rashmi, B.; Dhaliwal, L.K. Implication of the RAGE-EN-RAGE axis in endometriosis. Int. J. Gynecol. Obstet. 2010, 110, 199–202. [Google Scholar] [CrossRef]
- Zhang, X.; Nie, D.; Zhang, L.; Liu, X. Original Article Study on diagnostic values and pathological conditions of serum HGF and CA199 in endometriosis. Am. J. Transl. Res. 2021, 13, 2849–2857. [Google Scholar]
- Laudanski, P.; Szamatowicz, J.; Kowalczuk, O.; Kuźmicki, M.; Grabowicz, M.; Chyczewski, L. Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis. Hum. Reprod. 2009, 24, 1880–1890. [Google Scholar] [CrossRef] [Green Version]
- Kim, H.; Ku, S.Y.; Suh, C.S.; Kim, S.H.; Kim, J.H.; Kim, J.G. Association between endometriosis and polymorphisms in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptor and osteoprotegerin genes and their serum levels. Arch. Gynecol. Obstet. 2012, 286, 147–153. [Google Scholar] [CrossRef]
- Chang, H.-M.; Wu, H.-C.; Sun, Z.; Lian, F.; Leung, P.C.K. Neurotrophins and glial cell line-derived neurotrophic factor in the ovary: Physiological and pathophysiological implications. Hum. Reprod. Updat. 2019, 25, 224–242. [Google Scholar] [CrossRef]
- Streiter, S.; Fisch, B.; Sabbah, B.; Ao, A.; Abir, R. The importance of neuronal growth factors in the ovary. Mol. Hum. Reprod. 2015, 22, 3–17. [Google Scholar] [CrossRef] [Green Version]
- Asally, R.; Markham, R.; Manconi, F. The Expression and Cellular Localisation of Neurotrophin and Neural Guidance Molecules in Peritoneal Ectopic Lesions. Mol. Neurobiol. 2018, 56, 4013–4022. [Google Scholar] [CrossRef]
- Zhang, X.; Lin, J.; Qian, Y.; Deng, L. Decreased levels of interleukin-18 in peritoneal fluid but not in serum of patients with endometriosis. Fertil. Steril. 2004, 81, 1229–1234. [Google Scholar] [CrossRef]
- Oku, H.; Tsuji, Y.; Kashiwamura, S.-I.; Adachi, S.; Kubota, A.; Okamura, H.; Koyama, K. Role of IL-18 in pathogenesis of endometriosis. Hum. Reprod. 2004, 19, 709–714. [Google Scholar] [CrossRef] [Green Version]
- Glitz, C.; Souza, C.; Rodini, G.; Genro, V.; Bilibio, J.; Senger, M.; Cunha-Filho, J. Peritoneal and serum interleukin-18 levels are not increased in women with minimum or mild endometriosis. Braz. J. Med. Biol. Res. 2009, 42, 1039–1043. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.M.; Ma, Z.Y.; Song, N. Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α and peritoneal fluid flora were associated with infertility in patients with endometriosis. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 2513–2518. [Google Scholar] [CrossRef]
- Li, S.; Fu, X.; Wu, T.; Yang, L.; Hu, C.; Wu, R. Role of Interleukin-6 and Its Receptor in Endometriosis. Experiment 2017, 23, 3801–3807. [Google Scholar] [CrossRef] [Green Version]
- Luk, J.; Seval, Y.; Kayisli, U.A.; Ulukus, M.; Ulukus, C.E.; Arici, A. Regulation of Interleukin-8 Expression in Human Endometrial Endothelial Cells: A Potential Mechanism for the Pathogenesis of Endometriosis. J. Clin. Endocrinol. Metab. 2005, 90, 1805–1811. [Google Scholar] [CrossRef] [Green Version]
- Walsh, M.C.; Choi, Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003, 14, 251–263. [Google Scholar] [CrossRef] [PubMed]
- Tobeiha, M.; Moghadasian, M.H.; Amin, N.; Jafarnejad, S. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. BioMed Res. Int. 2020, 2020, 6910312. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ivanovska, M.; Abdi, Z.; Murdjeva, M.; Macedo, D.; Maes, A.; Maes, M. CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders. Pharmaceuticals 2020, 13, 230. [Google Scholar] [CrossRef] [PubMed]
- Tan, J.; Zou, Y.; Wu, X.-W.; Tian, L.-F.; Su, Q.; He, J.-X.; Huang, Z.-H.; Zhao, Y.; Wu, L.-P.; Wu, Q.-F. Increased SCF in Follicular Fluid and Granulosa Cells Positively Correlates With Oocyte Maturation, Fertilization, and Embryo Quality in Humans. Reprod. Sci. 2017, 24, 1544–1550. [Google Scholar] [CrossRef] [PubMed]
- Osuga, Y.; Koga, K.; Tsutsumi, O.; Igarashi, T.; Okagaki, R.; Takai, Y.; Matsumi, H.; Hiroi, H.; Fujiwara, T.; Momoeda, M.; et al. Stem Cell Factor (SCF) Concentrations in Peritoneal Fluid of Women with or without Endometriosis. Am. J. Reprod. Immunol. 2000, 44, 231–235. [Google Scholar] [CrossRef]
- Zhang, W.; Wang, H.; Sun, M.; Deng, X.; Wu, X.; Ma, Y.; Li, M.; Shuoa, S.M.; You, Q.; Miao, L. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun. 2020, 40, 69–80. [Google Scholar] [CrossRef] [Green Version]
- Zhou, J.; Chern, B.S.M.; Barton-Smith, P.; Phoon, J.W.L.; Tan, T.Y.; Viardot-Foucault, V.; Ku, C.W.; Tan, H.H.; Chan, J.K.Y.; Lee, Y.H. Peritoneal Fluid Cytokines Reveal New Insights of Endometriosis Subphenotypes. Int. J. Mol. Sci. 2020, 21, 3515. [Google Scholar] [CrossRef]
- OuYang, Z.; Osuga, Y.; Hirota, Y.; Hirata, T.; Yoshino, O.; Koga, K.; Yano, T.; Taketani, Y. Interleukin-4 induces expression of eotaxin in endometriotic stromal cells. Fertil. Steril. 2010, 94, 58–62. [Google Scholar] [CrossRef]
- Măluțan, A.M.; Drugan, T.; Ciortea, R.; Bucuri, C.; Rada, M.P.; Mihu, D. Endometriosis-associated changes in serum levels of interferons and chemokines. Turk. J. Med. Sci. 2017, 47, 115–122. [Google Scholar] [CrossRef]
- Suzumori, N.; Katano, K.; Suzumori, K. Peritoneal fluid concentrations of epithelial neutrophil-activating peptide-78 correlate with the severity of endometriosis. Fertil. Steril. 2004, 81, 305–308. [Google Scholar] [CrossRef] [PubMed]
- Wunder, D.M.; Mueller, M.D.; Birkhäuser, M.H.; Bersinger, N.A. Increased ENA-78 in the follicular fluid of patients with endometriosis. Acta Obstet. Et Gynecol. Scand. 2006, 85, 336–342. [Google Scholar] [CrossRef] [PubMed]
- Bertschi, D.; Mckinnon, B.D.; Evers, J.; Bersinger, N.A.; Mueller, M.D. Clinical Study Enhanced Inflammatory Activity of Endometriotic Lesions from the Rectovaginal Septum. Mediators Inflamm. 2013, 2013, 450950. [Google Scholar] [CrossRef] [PubMed]
- Burns, K.A.; Thomas, S.Y.; Hamilton, K.J.; Young, S.L.; Cook, D.N.; Korach, K.S. Early Endometriosis in Females Is Directed by Immune-Mediated Estrogen Receptor α and IL-6 Cross-Talk. Endocrinology 2017, 159, 103–118. [Google Scholar] [CrossRef] [Green Version]
- Perricos, A.; Wenzl, R.; Husslein, H.; Eiwegger, T.; Gstoettner, M.; Weinhaeusel, A.; Beikircher, G.; Kuessel, L. Does the Use of the “Proseek® Multiplex Oncology I Panel” on Peritoneal Fluid Allow a Better Insight in the Pathophysiology of Endometriosis, and in Particular Deep-Infiltrating Endometriosis? J. Clin. Med. 2020, 9, 2009. [Google Scholar] [CrossRef]
Figure 1.
Heat map representing the target proteins that showed a significantly different concentration in plasma of patients with endometriosis (patients with DIE and patients with endometriosis without DIE) compared to controls. The color intensity correlates with the expression level of the protein.
Figure 1.
Heat map representing the target proteins that showed a significantly different concentration in plasma of patients with endometriosis (patients with DIE and patients with endometriosis without DIE) compared to controls. The color intensity correlates with the expression level of the protein.
Figure 2.
Heat map representing the target proteins that showed a significantly different concentration in peritoneal fluid of patients with endometriosis (patients with DIE and patients with endometriosis without DIE) compared to controls. The color intensity correlates with the expression level of the protein.
Figure 2.
Heat map representing the target proteins that showed a significantly different concentration in peritoneal fluid of patients with endometriosis (patients with DIE and patients with endometriosis without DIE) compared to controls. The color intensity correlates with the expression level of the protein.
Figure 3.
Heat map representing the target proteins that showed a significantly different concentration in plasma of patients with deep-infiltrating endometriosis (DIE) and endometriosis patients without DIE. The color intensity correlates with the expression level of the protein.
Figure 3.
Heat map representing the target proteins that showed a significantly different concentration in plasma of patients with deep-infiltrating endometriosis (DIE) and endometriosis patients without DIE. The color intensity correlates with the expression level of the protein.
Figure 4.
Heat map representing the target proteins that showed a significantly different concentration in PF of patients with deep-infiltrating endometriosis (DIE) and endometriosis patients without DIE. The color intensity correlates with the expression level of the protein.
Figure 4.
Heat map representing the target proteins that showed a significantly different concentration in PF of patients with deep-infiltrating endometriosis (DIE) and endometriosis patients without DIE. The color intensity correlates with the expression level of the protein.
Table 1.
Patient characteristics.
| Patient Characteristics | Control Group (n = 30) | Endometriosis (n = 51) | p-Value | Endometriosis without DIE (n = 33) | Endometriosis with DIE (n = 18) | p-Value |
|---|---|---|---|---|---|---|
| General Information | ||||||
| Age (years) | 34.1 ± 5.97 | 32.9 ± 6.2 | 0.434 | 33.4 ± 5.98 | 32 ± 6.7 | 0.536 |
| BMI (kg/m²) | 25.2 (21.3–29.2) | 21.0 (20.2–24.9) | 0.015 | 21.1 (20.2–26.0) | 20.9 (19.8–22.9) | 0.430 |
| Gravidity | 1.5 ± 1.7 | 0.5 ± 1.1 | <0.001 | 0.7 ± 1.3 | 0.22 ± 0.55 | 0.171 |
| Parity | 0.6 ± 0.7 | 0.3 ± 0.8 | 0.04 | 0.45 ± 0.87 | 0.17 ± 0.51 | 0.183 |
| Preoperative pain symptoms | ||||||
| Dysmenorrhea n (%) | 29 (96.7%) | 48 (94.1%) | 0.609 | 32 (97%) | 16 (88.9%) | 0.282 |
| Dysmenorrhea Intensity (VAS) | 6.0 (4.0–8.0) | 5.0 (5.0–10.0) | 0.024 | 8 (5.5–10) | 7 (1.75–10.0) | 0.562 |
| Dyspareunia n (%) | 15 (50%) | 26 (51%) | 0.932 | 16 (48.5%) | 10 (55.6%) | 0.629 |
| Dyspareunia Intensity (VAS) | 2.0 (2.0–6.0) | 0.0 (0.0–6.0) | 0.856 | 0 (0.0–6.0) | 3.0 (3.0–5.0) | 0.950 |
| Influence of Pain on Sex Life n (%) | 11 (36.7%) | 19 (37.3%) | 0.958 | 11 (33.3%) | 8 (44.4%) | 0.433 |
| Influence of pain on Sex Life Intensity (VAS) | 0.0 (0.0–4.0) | 0.0 (0.0–5.0) | 0.752 | 0.0 (0.0–5.0) | 0.0 (0.0–4.25) | 0.682 |
| Cycle Phase | 0.620 | 0.918 | ||||
| Proliferative n (%) | 13 (43.3%) | 25 (49.0%) | 16 (48.5%) | 9 (50%) | ||
| Secretory n (%) | 17 (56.7%) | 26 (51.0%) | 17 (51.5%) | 9 (50%) | ||
| rASRM score n(%) | NA | 0.007 | ||||
| I | NA | 10 (19.6%) | 9 (27.3%) | 1 (5.6%) | ||
| II | NA | 8 (15.7%) | 7 (21.2%) | 1 (5.6%) | ||
| III | NA | 18 (35.3%) | 10 (30.3%) | 8 (44.4%) | ||
| IV | NA | 15 (29.4%) | 7 (21.2%) | 8 (44.4%) | ||
| Endometrioma n (%) | NA | 32 (62.7%) | NA | 23 (69.7%) | 9 (50.0%) | 0.164 |
| ENZIAN score n(%) | ||||||
| A 1–3 | NA | 13 (25.5%) | NA | NA | 13 (72.2%) | NA |
| B 1–3 | NA | 17 (33.3%) | NA | NA | 17 (94.4%) | NA |
| C 1–3 | NA | 6 (11.8%) | NA | NA | 6 (33.3%) | NA |
| FA | NA | 0 | NA | NA | 0 | NA |
| FI | NA | 0 | NA | NA | 0 | NA |
| FO | NA | 0 | NA | NA | 0 | NA |
Table legend: the statistically significant values are set in bold. DIE: deep-infiltrating endometriosis, BMI: body mass index, VAS: visual analog scale, rASRM: revised American Society of Reproductive Medicine score, NA: not applicable.
Table 2.
Proteins that were significantly increased or decreased in patients with endometriosis compared to controls.
Table 2.
Proteins that were significantly increased or decreased in patients with endometriosis compared to controls.
| Target Protein | Geom. Mean of Intensities in | Fold Change | p-Value | |
|---|---|---|---|---|
| Controls (n = 30) | Endometriosis (n = 51) | in Endometriosis | ||
| PLASMA | ||||
| EN-RAGE | 10.68 | 17.44 | 1.63 | 0.001 |
| hGDNF | 6.20 | 6.92 | 1.12 | 0.05 |
| CCL23 | 530.17 | 647.89 | 1.22 | 0.03 |
| TRAIL | 430.83 | 385.88 | 0.90 | 0.05 |
| HGF | 94.14 | 82.40 | 0.88 | 0.03 |
| 4E-BP1 | 50.38 | 72.20 | 1.43 | 0.04 |
| PERITONEAL FLUID | ||||
| IL-8 | 11.34 | 30.37 | 2.68 | 0.04 |
| IL-18 | 4.36 | 2.94 | 0.67 | 0.01 |
| IL-6 | 3.68 | 7.85 | 2.13 | 0.03 |
Table legend: Geom.: geometric, EN-RAGE: Receptor for Advanced Glycation End-products binding protein, CCL23: chemokine ligand 23, HGF: Hepatocyte Growth Factor, 4E-BP1: eukaryotic translation initiation factor 4E-binding protein 1, TRAIL: TNF-Related Apoptosis Inducing Ligand, hGDNF: human Glial-derived Neurotrophic factor, IL-18: Interleukin-18, IL-6: Interleukin-6, IL-8: Interleukin-8.
Table 3.
Proteins that were significantly increased or decreased in patients with deep-infiltrating endometriosis (DIE) compared to endometriosis patients without DIE.
Table 3.
Proteins that were significantly increased or decreased in patients with deep-infiltrating endometriosis (DIE) compared to endometriosis patients without DIE.
| Target Protein | Geom. Mean of Intensities in | Fold Change | p-Value | |
|---|---|---|---|---|
| Endometriosis without DIE (n = 33) | Endometriosis with DIE (n = 18) | in DIE | ||
| PLASMA | ||||
| CCL11 | 154.75 | 130.24 | 0.84 | 0.04 |
| TRANCE | 24.57 | 17.11 | 0.70 | 0.01 |
| PERITONEAL FLUID | ||||
| CCL23 | 11.18 | 19.06 | 1.70 | 0.004 |
| CCL11 | 5.52 | 8.08 | 1.46 | 0.03 |
| SCF | 7.21 | 8.85 | 1.23 | 0.04 |
| CXCL5 | 2.57 | 1.01 | 2.54 | 0.046 |
Table legend. Geom.: geometric, TRANCE: tumor necrosis factor-related activation-induced cytokine, CCL11: chemokine ligand 11, CCL23: chemokine ligand 23, SCF: Stem Cell Factor, CXCL5: C-X-C motif chemokine 5.
Table 4.
Summary of the characteristics of the target proteins that were significantly increased or decreased in patients with endometriosis compared to controls.
Table 4.
Summary of the characteristics of the target proteins that were significantly increased or decreased in patients with endometriosis compared to controls.
| Target | Relation of Factor in Endometriosis Compared to Controls PLASMA | Relation of Factor in Endometriosis Compared to Controls PF | Involved in | Characteristics |
|---|---|---|---|---|
| Receptor for Advanced Glycation End-products binding protein (EN-RAGE) | ↑ | NS | Inflammation Oxidative stress | |
| Chemokine ligand 23 (CCL23) | ↑ | NS | Chemotaxis Angiogenesis | |
| Hepatocyte Growth Factor (HGF) | ↓ | NS | Cell proliferation | |
| Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) | ↑ | NS | Tumor suppression | |
| TNF-Related Apoptosis Inducing Ligand (TRAIL) | ↓ | NS | Induction of apoptosis |
|
| human Glial-derived Neurotrophic factor (hGDNF) | ↑ | NS | Cell growth and survival |
|
| Interleukin-18 (IL-18) | NS | ↓ | Inflammation |
|
| Interleukin-6 IL-6 | NS | ↑ | Immune response |
|
| Interleukin-8 (IL-8) | NS | ↑ | Immune response Angiogenesis |
|
Table legend—↑: increased, ↓: decreased, NS: not significant, PF: peritoneal fluid, IL-1ß: Interleukin-1ß, TNF-alpha: Tumor Necrosis Factor-alpha, NF-kB: Nuclear Factor kappa B, NKT: natural killer T-cells, VEGF: Vascular Endothelial Growth Factor, ERP: Exported Repeated Protein, IL-2: Interleukin-2.
Table 5.
Summary of the characteristics of the target proteins that were significantly increased or decreased in patients with deep-infiltrating endometriosis (DIE) compared to endometriosis patients without DIE.
Table 5.
Summary of the characteristics of the target proteins that were significantly increased or decreased in patients with deep-infiltrating endometriosis (DIE) compared to endometriosis patients without DIE.
| Target | Relation of Factor in Patients with DIE Compared to Endometriosis Patients without DIE PLASMA | Relation of Factor in Patients with DIE Compared to Endometriosis Patients without DIE PF | Involved in | Characteristics |
|---|---|---|---|---|
| Tumor necrosis factor-related activation-induced cytokine (TRANCE) | ↓ | NS | Adaptive immunity | |
| Chemokine (C-C Motif) ligand 11 (CCL 11) | ↓ | ↑ | Allergic reaction |
|
| Chemokine ligand 23 (CCL23) | NS | ↑ | Inflammation | |
| Stem Cell Factor (SCF) | NS | ↑ | Innate immunity | |
| C-X-C motif chemokine 5 (CXCL5) | NS | ↑ | Adaptive immunity Angiogenesis |
|
Table legend—↑: increased, ↓: decreased, NS: not significant, PF: peritoneal fluid, VEGF: Vascular Endothelial Growth Factor.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Perricos, A.; Husslein, H.; Kuessel, L.; Gstoettner, M.; Weinhaeusel, A.; Eiwegger, T.; Beikircher, G.; Wenzl, R. Does the Use of the “Proseek® Multiplex Inflammation I Panel” Demonstrate a Difference in Local and Systemic Immune Responses in Endometriosis Patients with or without Deep-Infiltrating Lesions? Int. J. Mol. Sci. 2023, 24, 5022. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24055022
AMA Style
Perricos A, Husslein H, Kuessel L, Gstoettner M, Weinhaeusel A, Eiwegger T, Beikircher G, Wenzl R. Does the Use of the “Proseek® Multiplex Inflammation I Panel” Demonstrate a Difference in Local and Systemic Immune Responses in Endometriosis Patients with or without Deep-Infiltrating Lesions? International Journal of Molecular Sciences. 2023; 24(5):5022. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24055022
Chicago/Turabian StylePerricos, Alexandra, Heinrich Husslein, Lorenz Kuessel, Manuela Gstoettner, Andreas Weinhaeusel, Thomas Eiwegger, Gabriel Beikircher, and René Wenzl. 2023. "Does the Use of the “Proseek® Multiplex Inflammation I Panel” Demonstrate a Difference in Local and Systemic Immune Responses in Endometriosis Patients with or without Deep-Infiltrating Lesions?" International Journal of Molecular Sciences 24, no. 5: 5022. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24055022
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
